Quarterly report pursuant to Section 13 or 15(d)

Inventory

v3.20.2
Inventory
9 Months Ended
Aug. 31, 2020
Inventory Disclosure [Abstract]  
Inventory

Note 4– Inventory

Inventory is comprised of public cord blood banking specimens, collection kits, finished goods, work-in-process and raw materials.  Collection kits are used in the collection and processing of umbilical cord blood and cord tissue stem cells, finished goods include products purchased or assumed for resale and for the use in the Company’s processing and storage service.  Inventory in the Public Cord Blood Bank includes finished goods that are specimens that are available for resale.  The Company considers inventory in the Public Cord Blood Bank that has not completed all testing to determine viability to be work in process.  Due to changes in sales trends and estimated recoverability of cost capitalized into inventory, an impairment charge of $2,332,763 was recognized during the second quarter of fiscal 2019 to reduce inventory from cost to net realizable value.  The components of inventory at August 31, 2020 and November 30, 2019 are as follows:

 

 

 

As of

August 31,

2020

 

 

As of

November 30,

2019

 

Raw materials

 

$

 

 

$

 

Work-in-process

 

 

286,218

 

 

 

149,972

 

Work-in-process – Public Bank

 

 

 

 

 

 

Finished goods

 

 

43,855

 

 

 

52,451

 

Finished goods – Public Bank

 

 

13,134,828

 

 

 

13,491,375

 

Collection kits

 

 

35,622

 

 

 

44,453

 

Inventory reserve

 

 

(7,718

)

 

 

(7,718

)

Total inventory

 

$

13,492,805

 

 

$

13,730,533